Abstract

Human matrix metalloproteinase proMMP-9 is secreted as latent zymogen, which requires two-steps proteolytic activation. The secreted proMMP-9 is glycosylated at two positions: Asn38 and Asn120 located in the prodomain and catalytic domain, respectively. It has been demonstrated that glycosylation at Asn120 is required for secretion of the enzyme, while the role of Asn38 glycosylation is not well understood, but is usually linked to the activation process. One hypothesis stated that the Asn38 glycosylation might protect against proteolytic activation. However, the activation process occurs with or without the presence of this glycosylation. We conducted molecular dynamics (MD) simulations on the glycosylated and non-glycosylated proMMP-9 to elucidate the effect of Asn38 glycosylation on this two-step activation process. The simulation results suggest that Asn38 glycosylation does not hinder the activation process directly, but induces conformational changes in the vicinity of the first proteolytic region in such a way that E59-M60 cleavage is processed before R106-F107. These results correlate with analysis provided by Boon et al. and experimental data from Ogata et al. who attempted to determine the order of events in activation of proMMP-9. Results from additional MD simulations for the model of glycosylated proMMP-9 bound to galectin-8 N-domain suggest that Gal-8 by interacting with Asn38 glycan might further facilitate processing of the first cleavage between E59-M60. Thus, our simulation results suggest that both Asn38 glycosylation and interaction with Gal-8N may be involved in facilitating and the temporal order of the activation process of pro-MMP9. The aim of this report is to provide an inspiration for future detailed experiments aimed at explaining the role of N-glycosylation in the activation process of prodomain of MMP-9.

Highlights

  • Matrix metalloproteinase-9 (MMP-9), known as gelatinase B, is a Zn+2–dependent metalloendopeptidase [1] that is capable of degrading many extracellular matrix components

  • MMP-9 is tightly regulated at the expression level and by endogeneous inhibitors such as tissue inhibitors of metalloproteinase (TIMP) [5, 6]

  • They demonstrate that simulations are stable throughout the entire molecular dynamics (MD) simulations

Read more

Summary

Introduction

Matrix metalloproteinase-9 (MMP-9), known as gelatinase B, is a Zn+2–dependent metalloendopeptidase [1] that is capable of degrading many extracellular matrix components It plays an important role in normal tissue remodeling and pathological degradation of the extracellular matrix in several human autoimmune diseases, cancer metastasis, diabetes, and arthritis [2,3,4]. MMP-3 initially cleaves proMMP-9 at the E59-M60 located in the middle of the prodomain This proteolytic event triggers conformational change in proMMP-9 which exposes the R106-F107 peptide bond to the MMP-3 for the second cleavage event [17]. This stepwise activation mechanism is similar to that seen in other members of the MMP family such as MT1-MMP (MMP-14) [19], it is performed by different activating enzymes

Objectives
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call